多发性硬化症合作伙伴推进技术和健康解决方案中，患有多发性硬化症的人群对 SARS-CoV-2 疫苗的免疫球蛋白 G 反应。
Immunoglobulin G immune response to SARS-CoV-2 vaccination in people living with multiple sclerosis within Multiple Sclerosis Partners Advancing Technology and Health Solutions.
机构信息
Mellen Center, Neurological Institute, Cleveland Clinic, Cleveland, OH, USA.
Biogen, Cambridge, MA, USA.
出版信息
Mult Scler. 2022 Jun;28(7):1131-1137. doi: 10.1177/13524585211061343. Epub 2022 Jan 7.
BACKGROUND
The impact of multiple sclerosis (MS) disease-modifying therapies (DMTs) on SARS-CoV-2 vaccination response is uncertain.
METHODS
Post-SARS-CoV-2 vaccination blood samples across multiple DMTs were tested for SARS-CoV-2 immunoglobulin G (IgG) response.
RESULTS
Three hundred twenty-two people with MS were included; 91.9% received an mRNA vaccine. Post-vaccination reactive IgG rates (IgG index > 1) were 40% for anti-CD20 (32/80 patients); 41% for sphingosine 1-phosphate receptor modulators (S1PRM, 16/39); and 100% for all other classes, including the no DMT group.
CONCLUSION
Anti-CD20 therapies and S1PRMs reduce IgG response to SARS-CoV-2 vaccination; IgG response is preserved with other DMTs.
背景
多发性硬化症（MS）疾病修正治疗（DMT）对 SARS-CoV-2 疫苗接种反应的影响尚不确定。
方法
对多种 DMT 后的 SARS-CoV-2 疫苗接种后血液样本进行 SARS-CoV-2 免疫球蛋白 G（IgG）反应检测。
结果
共纳入 322 名 MS 患者，91.9%接受了 mRNA 疫苗。接种后反应性 IgG 率（IgG 指数>1）为抗 CD20（32/80 例）40%；鞘氨醇 1-磷酸受体调节剂（S1PRM，16/39）41%；其他所有类别均为 100%，包括无 DMT 组。
结论
抗 CD20 治疗和 S1PRM 降低了 SARS-CoV-2 疫苗接种的 IgG 反应；其他 DMT 可保留 IgG 反应。
Zotero 插件